Express Scripts, a company that controls about 40 percent of the pharmacy benefit market, will exclude an additional 64 drugs from its national …
In a research report issued today, Oppenheimer analyst Bret Jones maintained an Outperform rating on Express Scripts (NASDAQ:ESRX) with a price target of …